Register Login

Talaris Therapeutics Inc (TALS)

  • Event
  • June 30, 2022, 20:54 UTC

(10% Negative) TALARIS THERAPEUTICS, INC. (TALS) Announces Delay in reflected Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 11:21 a.m.

    📋 TALARIS THERAPEUTICS, INC. (TALS) - Clinical Trial Update

    Filing Date: 2022-06-30

    Accepted: 2022-06-30 16:54:13

    Event Type: Clinical Trial Update

    Event Details:

    Talaris Therapeutics Inc (TALS) Announces Clinical Trial Update Talaris Therapeutics Inc (TALS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: reflected, contained
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
      • Targeting ~20 sites in U.S. (17 active sites as of June 15, 2022

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Talaris Therapeutics Inc
    • CIK: 0001827506
    • Ticker Symbol: TALS
    • Period End Date: 2022-06-30
    • Document Type: 8-K

Search

News categories